Core Viewpoint - The innovative drug sector is experiencing significant growth, with multiple companies seeing substantial stock price increases, indicating a bullish trend in the market [1]. Group 1: Stock Performance - Shuyatain's stock price increased by 14.66%, reaching 26.52 [2] - Other notable performers include Dizhe Pharmaceutical with a 10.70% increase, Baili Tianheng at 10.63%, and Huana Pharmaceutical at 10.33% [2] - In the Hong Kong market, Keystone Pharmaceuticals surged over 18%, while CSPC Pharmaceutical and Xiansheng Pharmaceutical rose by over 12% and 8%, respectively [3] Group 2: Market Trends - The overall trend in the innovative drug sector shows a strong upward movement, with several companies hitting their daily price limits [1] - The performance of stocks in both mainland and Hong Kong markets reflects a growing investor confidence in the pharmaceutical industry [3]

重要内容提示： 湖南华纳大药厂股份有限公司（以下简称"华纳药厂"、"公司"、"本 公司"）控股股东湖南华纳医药投资合伙企业（有限合伙）（以下简称"华纳医药"） 拟以协议转让的方式将其持有的公司 11,079,600 股无限售条件流通股（占公司总 股本的 8.44%）转让给一致行动人湖南华纳至臻产业投资合伙企业（有限合伙） （以下简称"华纳至臻"）。 本次权益变动属于控股股东华纳医药增加一致行动人及在一致行动人内 部协议转让股份，不会导致公司控股股东及一致行动人的合计持股数量和比例发 生变化，不涉及增持或减持股份，亦不触及要约收购，不会使公司控股股东、实 际控制人发生变化。 本次权益变动尚需取得上海证券交易所出具的合规性确认意见，并在中 国证券登记结算有限责任公司上海分公司办理股份过户登记手续以及完成相关 法律法规要求可能涉及的其他批准。本次权益变动尚存在不确定性，敬请广大投 资者注意投资风险。 证券代码：688799 证券简称：华纳药厂 公告编号：2026-009 湖南华纳大药厂股份有限公司 关于控股股东增加一致行动人及在一致行动人内部 协议转让股份暨权益变动的提示性公告 本公司董事会、全体董事及相关股东保证 ...

湖南华纳大药厂股份有限公司 1 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权 益变动报告书》及其他相关的法律、法规和规范性文件编制。 简式权益变动报告书 上市公司名称：湖南华纳大药厂股份有限公司 股票上市地点：上海证券交易所 股票简称：华纳药厂 股票代码：688799 信息披露义务人一：湖南华纳医药投资合伙企业（有限合伙） 住所及通讯地址：浏阳经济技术开发区健康大道南路 5 号 信息披露义务人二：湖南华纳至臻产业投资合伙企业（有限合伙） 住所及通讯地址：浏阳经济技术开发区健寿大道 203 号欧洲城 C 栋 303 户 股份变动性质：新增一致行动人，股份在一致行动人之间转让，合计持股不变 签署日期：2026 年 3 月 24 日 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发行 证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本 报告书已全面披露了信息披露义务人在湖南华纳大药厂股份有限公司中拥有权 益的股份变动情况。 截至本报告书签署之日，除本报 ...

1、药品名称：二甲双胍恩格列净片（V） 证券代码：688799 证券简称：华纳药厂 公告编号：2026-008 湖南华纳大药厂股份有限公司 自愿披露关于获得药品注册证书的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的二甲双胍恩格列净片（V）《药品注册证书》，现将相关情况 公告如下： 一、药品相关信息 二甲双胍恩格列净片（V）配合饮食控制和运动，适用于正在接受恩格列净 和盐酸二甲双胍治疗的 2 型糖尿病成人患者，用于改善这些患者的血糖控制。公 2、剂型：片剂 3、规格：每片含盐酸二甲双胍 1000mg 与恩格列净 5mg 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、受理号：CYHS2402560 司二甲双胍恩格列净片（V）按新注册分类化学药品 4 类获得药品注册证书，视 同通过一致性评价。 7、药品批准文号：国药准字 H20263604 8、上市许可持有人：湖南华纳大药厂股份有限公司 9、审批结论：根据《中 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2026-007 湖南华纳大药厂股份有限公司 自愿披露关于子公司通过美国 FDA 现场检查的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南华纳大 药厂手性药物有限公司（以下简称"手性药物公司"）于 2025 年 11 月 10 日至 2025 年 11 月 14 日接受了来自美国食品药品监督管理局（以下简称"FDA"）的 药品批准前检查（PAI，Pre-Approval Inspection）。近日，公司收到手性药物公司 转发的美国 FDA 签发的现场检查报告（EIR，Establishment Inspection Report）， 该报告表明 FDA 确认本次检查已结束，手性药物公司通过本次现场检查。现将 相关情况公告如下： 一、FDA 现场检查的相关信息 接受检查企业名称：湖南华纳大药厂手性药物有限公司 企业生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道 139 号 检查事由：药品批准前检 ...

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd.'s subsidiary has successfully obtained GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for the active pharmaceutical ingredient fosfomycin trometamol, enabling market entry into Brazil and enhancing international competitiveness [1][2]. Group 1: Certification Details - The GMP certification was issued for Hunan Warner Pharmaceutical Chiral Drugs Co., Ltd. for the production of fosfomycin trometamol [1]. - The certification number is 1435341/23-6, and it is valid until January 19, 2028 [1]. - The production facility is located at 139 Tongguan Avenue, Tongguan Circular Economy Industrial Base, Wangcheng District, Changsha, Hunan Province [1]. Group 2: Product Information - Fosfomycin trometamol is used as an active ingredient in formulations for treating acute uncomplicated urinary tract infections caused by sensitive strains of Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter species, Enterobacter species, and Proteus mirabilis [1]. Group 3: Market Impact - The successful GMP certification lays a solid foundation for expanding into the Brazilian market and other international markets, thereby enhancing the company's international competitiveness [2].

Group 1: Company Performance - Cambrian achieved a net profit of 2.059 billion yuan in 2025, turning a profit due to a significant increase in revenue, which reached 6.497 billion yuan, a 453.21% increase year-on-year [1] - Muxi reported a total revenue of 1.644 billion yuan in 2025, a 121.26% increase, with net losses narrowing by 44.53% to 781.45 million yuan [2] - Moer Thread's revenue grew by 243.37% to 1.506 billion yuan in 2025, with net losses reduced by 36.70% to 1.024 billion yuan [3] - Lingdian Electric Control's net profit increased by 745.02% to 135 million yuan, despite a slight revenue decrease of 0.17% to 1.194 billion yuan [4] - JinkoSolar reported a net loss of 6.786 billion yuan in 2025, a decrease of 6,959.50%, with total revenue falling by 29.18% to 65.492 billion yuan [16] Group 2: Corporate Actions - Huicheng is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details still under discussion [5] - Zhongying Technology is planning to acquire at least 51% of Yingzhong Electric, which is expected to constitute a major asset restructuring [7] - Jierong Technology's actual controller is under investigation for suspected violations of information disclosure laws [6] Group 3: Market and Industry Trends - The AI industry is driving demand for computing power, benefiting companies like Cambrian and Moer Thread, which are expanding their market presence [1][3] - Muxi's GPU product shipments have significantly increased, reflecting strong market recognition and demand [2] - The global photovoltaic industry is facing price fluctuations and trade protection policies, impacting JinkoSolar's profitability [16]

证券代码：688799 证券简称：华纳药厂 公告编号：2026-006 湖南华纳大药厂股份有限公司 自愿披露关于子公司通过巴西国家卫生监督局 GMP 认证的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南 华纳大药厂手性药物有限公司（以下简称"手性药物公司"）收到巴西国家卫生 监督局（ANVISA）签发的药品生产质量管理规范（GMP）认证证书。现将相关 情况公告如下： 一、证书基本信息 生产企业：湖南华纳大药厂手性药物有限公司 三、对公司的影响及风险提示 生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道 139 号 认证编号：1435341/23-6 认证范围：化学原料药：磷霉素氨丁三醇 有效期限：2028 年 1 月 19 日 发证机关：巴西国家卫生监督局（ANVISA） 本次手性药物公司磷霉素氨丁三醇原料药顺利通过巴西国家卫生监督局的 GMP 认证，为该产品成功进入巴西市场创造了条件，对其进一步拓展巴西市场 和其他国际市场奠定坚实基础，有利于 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd., received the Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency, allowing the company to enter the Brazilian market with its chemical raw material drug, Phosphomycin Amino Butanol, which is valid until January 19, 2028 [1] Group 1 - The GMP certification enhances the company's international competitiveness by facilitating market entry in Brazil [1] - The certification specifically pertains to the production of Phosphomycin Amino Butanol, a chemical raw material drug [1] - The effective period of the GMP certification is until January 19, 2028 [1] Group 2 - The international raw material drug business in the pharmaceutical industry is subject to uncertainties due to national policies and changes in the overseas market environment [1]

Core Viewpoint - Warner Pharmaceuticals announced that its wholly-owned subsidiary, Chiral Pharmaceuticals, received a Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency for the active pharmaceutical ingredient fosfomycin trometamol, valid until January 19, 2028. This certification facilitates the entry of the product into the Brazilian market, enhancing international market expansion and competitiveness, although the international active pharmaceutical ingredient business faces uncertainties due to policy and market conditions [1]. Group 1 - The GMP certification is specifically for the active pharmaceutical ingredient fosfomycin trometamol [1] - The certification is valid until January 19, 2028 [1] - Fosfomycin trometamol is used in formulations for treating urinary tract infections [1] Group 2 - The certification creates conditions for the product's entry into the Brazilian market [1] - It is expected to aid in expanding international market presence and improving competitiveness [1] - The international active pharmaceutical ingredient business is subject to uncertainties influenced by policy and market environments [1]